Annual report pursuant to Section 13 and 15(d)

Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details)

v3.10.0.1
Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details)
3 Months Ended 12 Months Ended
Dec. 31, 2018
USD ($)
$ / shares
Sep. 30, 2018
USD ($)
$ / shares
Jun. 30, 2018
USD ($)
$ / shares
Mar. 31, 2018
USD ($)
$ / shares
Dec. 31, 2017
USD ($)
$ / shares
Sep. 30, 2017
USD ($)
$ / shares
Jun. 30, 2017
USD ($)
$ / shares
Mar. 31, 2017
USD ($)
$ / shares
Dec. 31, 2018
USD ($)
trading_day
$ / shares
Dec. 31, 2017
USD ($)
$ / shares
Dec. 31, 2016
USD ($)
$ / shares
Dec. 31, 2007
$ / shares
Jan. 01, 2018
USD ($)
Oct. 06, 2017
USD ($)
Jan. 01, 2017
USD ($)
May 03, 2016
Jan. 31, 2010
right
Basis of Presentation [Line Items]                                  
Unrealized gain on AFS investments                 $ 48,000 $ 144,000 $ (1,109,000)            
Maturity period of cash and cash equivalents, maximum                 3 months                
Write-downs related to obsolete inventory                 $ 0 0              
Retained earnings (accumulated deficit) $ (229,197,000)       $ (400,924,000)       (229,197,000) (400,924,000)              
Milestone payment received                 4,600,000                
Third-party portion of milestone payment received                 3,000,000.0                
Revenue recognized                 1,600,000                
Total revenues 50,465,000 $ 33,375,000 $ 27,995,000 $ 29,267,000 59,590,000 $ 45,663,000 $ 90,043,000 $ 56,157,000 251,453,000 141,102,000 108,973,000            
Net income (loss) $ (7,007,000) $ 8,426,000 $ 6,058,000 $ 5,079,000 $ (42,482,000) $ 67,362,000 $ 73,160,000 $ 45,279,000 $ 143,321,000 $ 12,556,000 $ (1,636,000)            
Earnings per share - diluted (USD per share) | $ / shares $ (0.33) $ 0.36 $ 0.26 $ 0.22 $ (2.02) $ 2.80 $ 2.99 $ 1.83 $ 5.96 [1] $ 0.53 [1] $ (0.08) [1]            
Share-based Compensation                                  
Dividend declared (USD per share) | $ / shares                       $ 2.50          
Gain on disposition of product line                     $ 1,100,000            
Provision for taxes on gain from discontinued operations                 $ 0 $ 0 408,000            
Equity component of currently redeemable convertible notes (Note 6) $ 0       $ 18,859,000       0 18,859,000              
Net cash used in investing activities                 (423,269,000) (79,179,000) (134,415,000)            
Net cash provided by operating activities                 194,059,000 88,570,000 60,733,000            
Net cash provided by financing activities                 $ 328,585,000 (7,523,000) (4,994,000)            
Stock Options | 2002 Stock Incentive Plan                                  
Share-based Compensation                                  
Award expiration period                 10 years                
Stock Options | Vest 1/8 on the six month anniversary of the date of grant | 2002 Stock Incentive Plan                                  
Share-based Compensation                                  
Award vesting period                 6 months                
Award vesting right (as a percent)                 12.50%                
Stock Options | Vest 1/48 each month for forty-two months | 2002 Stock Incentive Plan                                  
Share-based Compensation                                  
Award vesting period                 42 months                
Award vesting right (as a percent)                 2.08%                
Minimum                                  
Basis of Presentation [Line Items]                                  
Property and equipment, useful life                 3 years                
Maximum                                  
Basis of Presentation [Line Items]                                  
Property and equipment, useful life                 10 years                
Crystal                                  
Basis of Presentation [Line Items]                                  
Value of share consideration                           $ 10,500,000      
Metabasis Therapeutics                                  
Basis of Presentation [Line Items]                                  
Number of contingent value rights | right                                 4
Royalty Agreements                                  
Basis of Presentation [Line Items]                                  
Product royalty (as a percent)                               20.00%  
Palvella | Royalty Agreements                                  
Basis of Presentation [Line Items]                                  
Additional royalties receivable under sales-based milestones $ 8,000,000.0               $ 8,000,000.0                
Palvella | Royalty Agreements | Minimum                                  
Basis of Presentation [Line Items]                                  
Product royalty (as a percent) 5.00%               5.00%                
Palvella | Royalty Agreements | Maximum                                  
Basis of Presentation [Line Items]                                  
Product royalty (as a percent) 9.80%               9.80%                
Aziyo | Royalty Agreements                                  
Basis of Presentation [Line Items]                                  
Proceeds from royalties received                   10,000,000.0              
Product royalty (as a percent) 5.00%               5.00%                
Additional royalties receivable under sales-based milestones $ 10,000,000.0               $ 10,000,000.0                
Effective interest rate of forecasted cash flows (as a percent)                 26.00%                
CorMatrix | Royalty Agreements                                  
Basis of Presentation [Line Items]                                  
Product royalty (as a percent) 5.00%               5.00%                
Expiration period of royalty agreement                 10 years                
2023 Convertible Senior Notes | Senior Notes                                  
Share-based Compensation                                  
Principal amount outstanding $ 750,000,000.0               $ 750,000,000.0                
Interest on debt instrument (as a percent) 0.75%               0.75%                
2019 Convertible Senior Notes | Senior Notes                                  
Share-based Compensation                                  
Threshold business days for repayment of principal                 3 days                
Number of consecutive trading days | trading_day                 50                
Accounting Standards Update 2016-09                                  
Share-based Compensation                                  
Cumulative-effect adjustment from adoption of ASU                             $ 18,103,000    
Accounting Standards Update 2014-09                                  
Share-based Compensation                                  
Cumulative-effect adjustment from adoption of ASU                         $ 25,581,000        
Accounting Standards Update 2016-01                                  
Share-based Compensation                                  
Cumulative-effect adjustment from adoption of ASU                         0        
Accounting Standards Update 2016-15                                  
Share-based Compensation                                  
Net cash used in investing activities                   (5,000,000.0) (8,800,000)            
Net cash provided by operating activities                   5,000,000 2,300,000            
Net cash provided by financing activities                     6,500,000            
AOCI Including Portion Attributable to Noncontrolling Interest | Accounting Standards Update 2016-01                                  
Share-based Compensation                                  
Cumulative-effect adjustment from adoption of ASU                         (2,700,000)        
Retained Earnings                                  
Basis of Presentation [Line Items]                                  
Net income (loss)                 $ 143,321,000 12,556,000 (1,636,000)            
Retained Earnings | Accounting Standards Update 2016-09                                  
Share-based Compensation                                  
Cumulative-effect adjustment from adoption of ASU                             $ 17,647,000    
Retained Earnings | Accounting Standards Update 2014-09                                  
Share-based Compensation                                  
Cumulative-effect adjustment from adoption of ASU                         25,581,000        
Retained Earnings | Accounting Standards Update 2016-01                                  
Share-based Compensation                                  
Cumulative-effect adjustment from adoption of ASU                         2,662,000        
Difference between Revenue Guidance in Effect before and after Topic 606 | Accounting Standards Update 2014-09                                  
Basis of Presentation [Line Items]                                  
Retained earnings (accumulated deficit)                         $ (25,600,000)        
Dividend yield                                  
Share-based Compensation                                  
Measurement input 0               0                
Palvella | Director                                  
Basis of Presentation [Line Items]                                  
Ownership in entity by director (as a percent)                 2.00%                
Royalties                                  
Basis of Presentation [Line Items]                                  
Total revenues                 $ 128,556,000 88,685,000 59,423,000            
Royalties | Calculated under Revenue Guidance in Effect before Topic 606                                  
Basis of Presentation [Line Items]                                  
Total revenues                 121,000,000.0 88,700,000 59,400,000            
Royalty, Promacta                                  
Basis of Presentation [Line Items]                                  
Total revenues                 99,300,000                
Royalty, Promacta | Calculated under Revenue Guidance in Effect before Topic 606                                  
Basis of Presentation [Line Items]                                  
Total revenues                 92,300,000 62,900,000 43,000,000.0            
Royalty, Kyprolis                                  
Basis of Presentation [Line Items]                                  
Total revenues                 21,700,000                
Royalty, Kyprolis | Calculated under Revenue Guidance in Effect before Topic 606                                  
Basis of Presentation [Line Items]                                  
Total revenues                 20,900,000 16,400,000 12,100,000            
Royalty, Evomela                                  
Basis of Presentation [Line Items]                                  
Total revenues                 5,700,000                
Royalty, Evomela | Calculated under Revenue Guidance in Effect before Topic 606                                  
Basis of Presentation [Line Items]                                  
Total revenues                 5,700,000 7,200,000 1,400,000            
Royalty, Other                                  
Basis of Presentation [Line Items]                                  
Total revenues                 1,900,000                
Royalty, Other | Calculated under Revenue Guidance in Effect before Topic 606                                  
Basis of Presentation [Line Items]                                  
Total revenues                 $ 2,100,000 $ 2,200,000 $ 2,900,000            
[1] The sum of net income per share amounts may not equal the total due to rounding